在临床前阿尔茨海默氏症中减缓驾驶反应时间
Pedram Ahmadnezhad1, Jeffrey M Burns2, Abiodun E Akinwuntan1,3
1University of Kansas Medical Center, Kansas City, KS, USA.
概括
患有临床前阿尔茨海默氏症 (AD) 个体在没有分心的情况下,对紧急情况的驾驶反应时间 (DRT) 较慢. 这一发现影响了早期阿尔茨海默病的老年人驾驶安全.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 运输安全运输安全
背景情况:
- 驾驶反应时间 (DRT) 对老年人的安全至关重要.
- 临床前阿尔茨海默氏症 (AD) 涉及微妙的认知变化,可能会影响驾驶.
- 在临床前AD中对紧急事件的DRT尚未研究.
研究的目的:
- 与对照人群相比,研究在临床前AD患者中对紧急事件的DRT.
- 评估认知负载 (分心) 对临床前AD的DRT的影响.
主要方法:
- 一项驾驶模拟器研究比较了19名患有临床前AD的司机和21名对照.
- 参与者执行了汽车追踪任务,有和没有分心器.
- 一个紧急事件 (模拟碰撞) 要求参与者制动和机动.
主要成果:
- 临床前AD的司机在没有分心的驾驶过程中表现出明显更长的DRT (7.56 ± 1.46秒) 比对照组 (6.42 ± 1.17秒) (p = .02).
- 当引入额外的任务 (分心) 时,没有观察到DRT中任何显著的群体差异.
- 这些试点结果表明,在非分心驾驶场景中存在特定的漏洞.
结论:
- 临床前AD可能会损害驾驶对紧急情况的反应时间,特别是在低认知负载下.
- 对于患有早期阿尔茨海默症的老年人来说,驾驶安全的影响需要在路上研究中进一步调查.
- 未来的研究应该探索现实世界的驾驶性能和认知负载的作用.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.0K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
Alzheimer's Disease: Treatment
147
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
147
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422
